EUVIMEDEUVIMED entdecken
Klinische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial

Wirkungen einer optimierten Beta-Glucan-basierten Formulierung auf Symptome, Funktionskapazität und systemische Entzündung bei Patient:innen mit COPD: randomisierte kontrollierte Studie

Supamas Napavichayanun, Rungnapha Yamdech, Sarocha Cherdchom, Apisara Suriyakul, Tippawan Phetngam, Syed Mahmood, Pornanong Aramwit

Frontiers in Pharmacology · 03.11.2026 · 17

DOI: 10.3389/fphar.2026.1938897 ↗

Auf einen Blick

In einer 12-wöchigen randomisierten Studie bei stabiler COPD führte Pro β-Glucan+® zu Verbesserungen bei einigen klinischen Endpunkten, nicht aber beim primären Endpunkt FEV 1 .

Fragestellung

Wirkt eine optimierte Kombination aus Beta-Glucan, Brokkoli-Extrakt und Quercetin bei stabiler COPD klinisch wirksam?

Methode

12-wöchige randomisierte, doppelblinde, placebokontrollierte Studie; 42 randomisiert, 38 in der Endanalyse; Pro β-Glucan+® vs. Placebo.

Ergebnisse

38 Teilnehmende: Pro β-Glucan+®, n = 19; Placebo, n = 19. Verbesserungen innerhalb der Gruppe bei Dyspnoe, respiratorischen Symptomen, Funktionskapazität und Gesundheitsstatus; Unterschied zwischen den Gruppen bei mMRC und CAT nach 12 Wochen. Kein Unterschied bei FEV 1 oder Biomarkern.

Schlussfolgerung der Autor:innen

Die optimierte Pro β-Glucan+®-Formulierung zeigte in vitro biologische Aktivität und war mit Verbesserungen mehrerer klinischer Outcomes bei stabiler COPD verbunden.

Kernaussagen

  • Kein signifikanter Unterschied beim primären Endpunkt FEV 1
  • Zwischen den Gruppen unterschieden sich mMRC und CAT nach 12 Wochen
  • Keine Unterschiede bei inflammatorischen oder oxidativen Biomarkern

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.11.2026. Verfasst von Supamas Napavichayanun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Center of Excellence in Bioactive Resources for Innovative Clinical Applications, Faculty of Pharmaceutical Sciences…. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chulalongkorn University.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, chronic inflammation, and oxidative stress, leading to progressive functional impairment and reduced quality of life. Beta-glucan possesses immunomodulatory and anti-inflammatory properties, but its therapeutic potential in COPD remains poorly defined. This study aimed to optimize a combined formulation of beta-glucan, broccoli extract, and quercetin (Pro β-Glucan+) through in vitro evaluation and to investigate its clinical efficacy in patients with stable COPD.

Methods

HFL1 lung fibroblasts were treated with different ratios of Pro β-Glucan+®, and cell viability and wound healing assays were performed to identify the optimal formulation. The selected ratio was evaluated in a 12-week randomized, double-blind, placebo-controlled trial. A total of 42 participants were randomized, of whom 38 completed the study and were included in the final analysis (Pro β-Glucan+, n = 19; placebo, n = 19). Prespecified primary outcome was FEV 1 . Secondary outcomes included clinical symptoms, functional capacity, health status, inflammatory and oxidative stress biomarkers, and patient satisfaction.

Results

The 10:3:2 ratio (beta-glucan:broccoli extract:quercetin) significantly enhanced HFL1 cell cell viability and wound healing activity among the tested formulations and was selected for clinical evaluation. Pro β-Glucan+® was well tolerated and associated with within-group improvements in dyspnea, respiratory symptoms, functional capacity, and health status after 12 weeks, with significant between-group differences in mMRC and CAT scores at week 12. No significant within- or between-group difference was observed in the prespecified primary outcome, FEV 1 , or in systemic inflammatory and oxidative stress biomarkers. Patient satisfaction was higher with Pro β-Glucan+® than with placebo.

Conclusion

The optimized Pro β-Glucan+® formulation demonstrated in vitro biological activity and was associated with improvements in several clinical outcomes in patients with stable COPD. Significant between-group differences were observed in mMRC and CAT scores at week 12. These findings support further investigation of this combination as an adjunctive nutritional intervention for COPD management. Clinical Trial Registration https://clinicaltrials.gov/study/NCT05878834 , identifier NCT05878834.

Schlagwörter

Stichwörter der Autor:innen

COPDbeta-glucanchronic obstructive pulmonary diseasefunctional capacityimmunomodulationinflammationoxidative stress

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Center of Excellence in Bioactive Resources for Innovative Clinical Applications, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Nanomedicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Internal Medicine, Police General Hospital, Bangkok, Thailand.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Malaya KualaLumpur, KualaLumpur, Malaysia.
  • The Academy of Science, The Royal Society of Thailand, Bangkok, Thailand.
  • Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand.

Förderung

  • Chulalongkorn University

Zitieren

APA

Napavichayanun, S., Yamdech, R., Cherdchom, S., Suriyakul, A., Phetngam, T., Mahmood, S., & Aramwit, P. (2026). Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1938897

Vancouver

Napavichayanun S, Yamdech R, Cherdchom S, Suriyakul A, Phetngam T, Mahmood S, et al. Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1938897

BibTeX
@article{Napavichayanun2026,
  author = {Napavichayanun, Supamas and Yamdech, Rungnapha and Cherdchom, Sarocha and Suriyakul, Apisara and Phetngam, Tippawan and Mahmood, Syed and Aramwit, Pornanong},
  title = {Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1938897}
}
Kostenlos starten →